JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

Search

Cencora Inc

Aperta

SettoreSettore sanitario

305.61 -2.05

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

298.7

Massimo

312.67

Metriche Chiave

By Trading Economics

Entrata

906M

566M

Vendite

2.2B

86B

P/E

Media del settore

37.19

67.147

EPS

4.08

Rendimento da dividendi

0.73

Margine di Profitto

0.659

Dipendenti

47,000

EBITDA

858M

1B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+29.04% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.73%

2.36%

Utili prossimi

6 mag 2026

Prossima data del Dividendo

1 giu 2026

Prossima data del' Ex Dividendo

15 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-10B

60B

Apertura precedente

307.66

Chiusura precedente

305.61

Notizie sul Sentiment di mercato

By Acuity

7%

93%

6 / 348 Classifica in Healthcare

Cencora Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 apr 2026, 23:53 UTC

Utili

Naver Posts Weaker First-Quarter Earnings

29 apr 2026, 23:41 UTC

Azioni calde

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 apr 2026, 23:55 UTC

Utili

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 apr 2026, 23:54 UTC

Utili

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 apr 2026, 23:52 UTC

Utili

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 apr 2026, 23:51 UTC

Utili

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 apr 2026, 23:51 UTC

Discorsi di Mercato

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 apr 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 apr 2026, 23:24 UTC

Utili

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 apr 2026, 23:24 UTC

Utili

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 apr 2026, 23:24 UTC

Utili

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 apr 2026, 23:24 UTC

Utili

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 apr 2026, 23:22 UTC

Utili

China Longyuan 1Q Net CNY1.70B, Down 14%

29 apr 2026, 23:22 UTC

Utili

China Longyuan: Power Generation Down 2.9% as of End-March

29 apr 2026, 23:20 UTC

Utili

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 apr 2026, 23:20 UTC

Utili

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 apr 2026, 23:19 UTC

Utili

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 apr 2026, 23:19 UTC

Utili

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 apr 2026, 23:19 UTC

Utili

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 apr 2026, 23:19 UTC

Utili

China Vanke 1Q Loss Narrows>000002.SZ

29 apr 2026, 23:18 UTC

Utili

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 apr 2026, 23:17 UTC

Utili

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 apr 2026, 23:15 UTC

Utili

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 apr 2026, 23:15 UTC

Utili

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 apr 2026, 23:13 UTC

Utili

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 apr 2026, 23:12 UTC

Utili

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 apr 2026, 23:11 UTC

Utili

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 apr 2026, 23:11 UTC

Utili

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 apr 2026, 23:04 UTC

Utili

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 apr 2026, 23:04 UTC

Utili

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Confronto tra pari

Modifica del prezzo

Cencora Inc Previsione

Obiettivo di Prezzo

By TipRanks

29.04% in crescita

Previsioni per 12 mesi

Media 401.86 USD  29.04%

Alto 429 USD

Basso 360 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cencora Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

6

Acquista

2

Mantieni

0

Vendi

Sentiment

By Acuity

6 / 348 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Cencora Inc

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
help-icon Live chat